There are no effective treatments for
leiomyosarcoma (LMS) spreading intraabdominally. The aim of this study was to develop precision
chemotherapy for recurrent peritoneal LMS
metastases in a patient-derived orthotopic xenograft (PDOX) model. The LMS PDOX models were established orthotopically on the dome of the bladder of nude mice. The LMS PDOX models were randomized into 6 groups when the
tumor volume reached 80 mm3: G1: untreated control; G2:
doxorubicin (DOX) (DOX: i.p., 3 mg/kg, weekly, 3 weeks); G3: DOX combined with
olaratumab (OLA) (DOX: i.p., 3 mg/kg, weekly, 3 weeks; OLA: i.p., 40 mg/kg, 3 times/week, 3 weeks); G4:
gemcitabine (GEM) combined with
docetaxel (DOC) (GEM: i.p., 100 mg/kg, weekly, 3 weeks; DOC: i.p., 20 mg/kg, weekly, 3 weeks); G5:
pazopanib (PAZ) (PAZ: p.o., 100 mg/kg, daily, 3 weeks); G6:
palbociclib (PAL) (PAL: p.o., 100 mg/kg, daily, 3 weeks). All mice were sacrificed on day 22.
Body weight was assessed twice a week.
Tumor volume was measured on day 0 and day 22. Although all regimens had a significant efficacy compared to the untreated group (P < 0.001), only GEM combined with DOC regressed the
tumor significantly (P < 0.001), suggesting GEM combined with DOC has clinical potential for this LMS patient.